ProfoundBio is a clinical-stage biotechnology company focused on developing novel antibody-based therapeutics for patients with cancer. Built on internally developed, proprietary technology platforms, the company has assembled a pipeline of multiple ADC drug candidates targeting solid tumors and hematological malignancies. Its disclosed pipeline includes rinatabart sesutecan (Rina-S; PRO1184) targeting FRα, PRO1160 targeting CD70, PRO1107 targeting PTK7, and PRO1286, a bispecific ADC targeting two broadly expressed solid tumor antigens. The company intends to use the new funds to support development of its differentiated clinical-stage ADC pipeline, including the planned pivotal trial of Rina-S. ProfoundBio strengthened its board with the addition of Andrew Lam (Ally Bridge Group) and independent directors Eric Dobmeier and Enoch Kariuki. Leadership is led by CEO and co-founder Baiteng Zhao and COO/CFO Erin Lavelle.

Total raised

$112M

Funding rounds

1

Latest round

Series B

Latest activity

Feb 2024